Ux023-Cl401
Research payments
$4,989,325
Through program year 2022, $4,989,325 in research payments was reported against Ux023-Cl401, across 352 payments, paid by Ultragenyx Pharmaceutical Inc..
- Paid by
- Ultragenyx Pharmaceutical Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $1,987,382 | 140 |
| 2021 | Research | $723,008 | 22 |
| 2020 | Research | $1,195,842 | 101 |
| 2019 | Research | $1,083,094 | 89 |
Breakdown
Usually the institution or organisation running the study, not a person.
Only reported on some payments, and a payment can report more than one category, so these amounts overlap.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Suzanne Jan De Beur Baltimore, MD Named on 40 payments
- Michael Levine Philadelphia, PA Named on 19 payments
- Neil Paloian Madison, WI Named on 19 payments
- Laila Tabatabai Houston, TX Named on 12 payments
- Thomas Carpenter New Haven, CT Named on 10 payments
- Thomas Weber Durham, NC Named on 9 payments
- Halley Wasserman Cincinnati, OH Named on 8 payments
- Anna Ryabets-Lienhard Los Angeles, CA Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.